K5t7S

antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010;127(1-
3):19-30.
272. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release
quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results
of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540-9.
273. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al. Extended-release
quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder
(MDD) in patients with an inadequate response to ongoing antidepressant treatment: A
multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol.
2010;13(7):917-32.
274. McIntyre A, Gendron A. Quetiapine adjunct to selective serotonin reuptake inhibitors or
venlafaxine in patients with major depression, comorbid anxiety, and residual depressive
symptoms: a randomized, placebo-controlled pilot study. Depress anxiety. 2007;24(7):487-94.
275. Doree JP, Des Rosiers J, Lew V, Gendron A, Elie R, Stip E, et al. Quetiapine augmentation
of treatment-resistant depression: a comparison with lithium. Current medical research and
opinion. 2007;23(2):333-41.
276. Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Katsuki A, Hayashi K, et al.
Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase
of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant
depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):308-12.
277. National Institute for Clinical Excellence (NICE). Depression: management of depression in
primary and secondary care. London: National Clinical Practice Guideline number 23; 2004.
278. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A
comparison of lithium and T(3) augmentation following two failed medication treatments for
depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-30.
279. Gervasoni N, Aubry JM, Gex-Fabry M, Bertschy G, Bondolfi G. Is there a place for tricyclic
antidepressants and subsequent augmentation strategies in obtaining remission for patients
with treatment resistant depression? Pharmacol Res. 2009;59(3):202-6.
280. Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J. Lamotrigine as adjunct
to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry.
2002;63(4):337-44.
281. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of
augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine
for resistant major depressive episodes. J Clin Psychiatry. 2003;64(4):403-7.
282. Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with
lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled,
double-blind study. Prim Care Companion J Clin Psychiatry. 2008;10(3):187-90.
283. Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment
resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol.
2007;22(3):179-82.
284. Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, et al. A
double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent
in treatment-refractory unipolar depression. J Clin Psychiatry. 2011;72(10):1405-12.
285. Mowla A, Kardeh E. Topiramate augmentation in patients with resistant major depressive
disorder: a double-blind placebo-controlled clinical trial. Prog Neuropsychopharmacol Biol
Psychiatry. 2011;35(4):970-3.
254
GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS